Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT03099174
Title This Study in Patients With Different Types of Cancer (Solid Tumours) Aims to Find a Safe Dose of Xentuzumab in Combination With Abemaciclib With or Without Hormonal Therapies. The Study Also Tests How Effective These Medicines Are in Patients With Lung and Breast Cancer.
Recruitment Active, not recruiting
Gender both
Phase Phase I
Variant Requirements No
Sponsors Boehringer Ingelheim
Indications

Advanced Solid Tumor

breast cancer

lung non-small cell carcinoma

Therapies

Abemaciclib + Xentuzumab

Abemaciclib + Letrozole + Xentuzumab

Abemaciclib + Anastrozole + Xentuzumab

Abemaciclib + Fulvestrant + Xentuzumab

Age Groups:
Covered Countries USA | FRA | ESP


No variant requirements are available.